Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional PDT with ALA for Basal Cell Carcinoma
NCT00747903Phase 2
Key facts
- Status
- Unknown
- Start
- Feb 2008
- Primary completion
- Dec 2010
- Countries
- 1
- Sponsor
- Laser & Skin Surgery Center of New York
- Modality
- Small Molecules
- Conditions
- basal cell carcinoma (BCC)
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in basal cell carcinoma (BCC), sponsored by Laser & Skin Surgery Center of New York. Primary endpoints: Safety and Efficacy. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Intralesional PDT
Intralesional aminolevulinic acid + Blue Light
03
Who it enrols
Patients with biopsy-proven nodular basal cell carcinoma on the trunk or extremities, tumor size <= 2 cm, who are not immunocompromised and have no history of keloids or photosensitivity.
04
Endpoints
Primary
Safety
Efficacy
Secondary
Healing Time
Clinical Improvement
Histological Clearance
Beyond the preview
Go deeper on NCT00747903.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00747903.